Part two: an unblinded, parallel, randomized study to assess nicotine pharmacokinetics of four Vuse Solo ENDS flavors in smokers.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Keyser (2023)
Tracing the movement of electronic cigarette flavor chemicals and nicotine from refill fluids to aerosol, lungs, exhale, and the environment.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Khachatoorian (2022)
Comparing the Effects of the EU- Versus the US-JUUL Pod in a Sample of UK Smokers: Nicotine absorption, Satisfaction, and Other Nicotine-Related Subjective Effects.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Kimber (2023)
Reinforcement enhancement by nicotine: a novel abuse-liability assessment of e-cigarettes in young adults.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Kirshenbaum (2022)
Dripping and vape tricks: alternative e-cigarette use behaviors among adolescents.
Individual Clinical
Pharmacokinetics & Abuse Liability
Misuse Potential
Kong (2020)
E-cigarette device type and combustible tobacco use: Results from a pooled analysis of 10,482 youth.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Kong (2022)
Molecular and neuronal mechanisms underlying the effects of adolescent nicotine exposure on anxiety and mood disorders.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Laviolette (2021)
Variations in coil temperature/power and e‐liquid constituents change size and lung deposition of particles emitted by an electronic cigarette
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Lechasseur (2019)
Nicotine Dependence of Electronic Cigarette, Dual Combustible and Electronic Cigarette Users.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Lee (2021)
Further investigation of gateway effects using the PaTh study.
Individual Clinical
Pharmacokinetics & Abuse Liability
Abuse Liability
Lee (2020)